Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically ...

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide ...

Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has ...

Viatris Inc. (NASDAQ:VTRS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 9, Barclays ...

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market ...

Given Ajanta’s improving business mix and robust cash generation, its share valuation appears reasonable for a company ...

Four pharma stocks to watch today as Lupin signs a peptide API deal, Dr Reddy’s and Aurobindo face FDA observations, and Biocon clears a global launch.

Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent ...

Biocon’s subsidiary Biocon Pharma has received the Food and Drug Administration’s permission for norepinephrine bitartrate injection (4 mg/4 ml, 1 mg/ml) in a single-dose vial, the company said in a ...

Yogesh Agrawal, MD of Ajanta Pharma outlined Ajanta Pharma’s strategy to capitalise on the opportunity through its ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Roche ($RHHBY) could have Indian competition for Herceptin sooner than it thought. Now that the Swiss drugmaker has decided to forego a patent fight over the breast ...